LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Kodu・Aktsiate loetelu・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Suletud

SektorTervishoid

3.22 -1.23

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.18

Max

3.26

Põhinäitajad
By Trading Economics
Sissetulek	-21M 41M
Müük	59M 107M
P/E Sektori keskmine	5.581 49.888
Aktsiakasum	0.24
Kasumimarginaal	38.282
Töötajad	100
EBITDA	64M 73M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+44.51% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-186M 570M
Eelmine avamishind	4.45
Eelmine sulgemishind	3.22

Uudiste sentiment

By Acuity

50%

147 / 344 Pingereas Healthcare

Ironwood Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. juuni 2026, 20:30 UTC

Tulu

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2. juuni 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2. juuni 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. juuni 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2. juuni 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2. juuni 2026, 23:01 UTC

Omandamised, ülevõtmised, äriostud

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2. juuni 2026, 23:01 UTC

Omandamised, ülevõtmised, äriostud

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2. juuni 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2. juuni 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2. juuni 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2. juuni 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. juuni 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2. juuni 2026, 21:00 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2. juuni 2026, 20:46 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:38 UTC

Tulu

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2. juuni 2026, 20:21 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:12 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Product Rev $594M

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Adj EPS 85c >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Loss $177M >PANW

Võrdlus sarnastega

Hinnamuutus

Ironwood Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

44.51% tõus

12 kuu keskmine prognoos

Keskmine 5 USD 44.51%

Kõrge 5 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Ironwood Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Ironwood Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

147 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.